Estimation of ?needs? and ?probable uptake? for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study)

Esparza, José; Chang, Marie Louise; Widdus, Roy; Madrid, Yvette; Walker, Neff; Ghys, Peter D.

doi:10.1016/s0264-410x(02)00775-2

Cited by 34 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High levels of vaccine uptake among communities at risk for HIV infection will be required to achieve effective reduction of HIV transmission with low to moderate efficacy vaccines [10,11]. Yet a recent WHO-UNAIDS panel of experts estimated future global HIV vaccine uptake at only 38% of the projected need in the case of vaccines with high (>70%) efficacy and only 19% of projected need in the case of vaccines with low to moderate (30-50%) efficacy [12]. Thus, acceptability may be low for "partial efficacy" HIV vaccines.…”

Section: Introductionmentioning

confidence: 99%

HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics

Newman

Duan²,

Lee³

et al. 2006

Vaccine

View full text Add to dashboard Cite

HIV vaccines offer the best long-term hope of controlling the AIDS pandemic; yet, the advent of HIV vaccines will not ensure their acceptability. We conducted a cross-sectional survey (n = 143), incorporating conjoint analysis, to assess HIV vaccine acceptability among participants recruited using multi-site (n = 9), venue-based sampling in Los Angeles. We used a fractional factorial experimental design to construct eight hypothetical HIV vaccines, each with seven dichotomous attributes. The acceptability of each vaccine was assessed individually and then averaged across participants. Next, the impact of each attribute on vaccine acceptability was estimated for each participant using ANOVA and then analyzed across participants. Acceptability of the eight hypothetical HIV vaccines ranged from 33.2 (S.D. 34.9) to 82.2 (S.D. 31.3) on a 0-100 scale; mean = 60.0 (S.D. 21.9). Efficacy had the greatest impact on acceptability (22.7; CI: 18.5-27.1; p < 0.0001), followed by cross-clade protection (12.5; CI: 8.7-16.3, p < 0.0001), side effects (11.5; CI: 7.4-15.5; p < 0.0001), and duration of protection (6.1; CI: 3.2-9.0; p < .0001). Route of administration, number of doses and cost were not significant. Low acceptability of "partial efficacy" vaccines may present obstacles to future HIV vaccine dissemination. Educational and social marketing interventions may be necessary to ensure broad HIV vaccine uptake.

show abstract

Section: Introductionmentioning

confidence: 99%

HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics

Newman

Duan²,

Lee³

et al. 2006

Vaccine

View full text Add to dashboard Cite

show abstract

“…The authors estimated that the government would need to purchase 532,000 doses initially and would require 15,000 doses annually to maintain vaccination levels for eight target population groups. 2 While a useful start in terms of conceptualizing the government response, this and other estimates of potential public sector demand based on public health "need" [9,10] assume that individuals offered a vaccine will agree to be vaccinated. Yet, AIDS is a highly stigmatized disease in most countries, so it is unlikely that everyone would agree to be vaccinated, affecting the coverage and effectiveness of a vaccination program.…”

Section: Introductionmentioning

confidence: 99%

The private demand for an AIDS vaccine in Thailand

et al. 2005

View full text Add to dashboard Cite

“…With the exception of the study of Esparza et al (2003), other estimates of vaccine requirements have not taken these factors into consideration explicitly. The model also improves on earlier estimates of vaccine requirements by using projections of the future population (taking into account changing population size and the effect of AIDS up to the time that the vaccine is distributed) rather than using a fixed population set at current estimates.…”

Section: 3mentioning

confidence: 99%

The potential effect of an HIV/AIDS vaccine in South Africa

Johnson¹,

Dorrington²

2007

S. A. Act. J.

View full text Add to dashboard Cite

This paper presents a model for assessing the potential effect of an HIV/AIDS vaccine in South Africa, and for calculating the amount of vaccine that would be required. A number of different hypothetical vaccine profiles and vaccine distribution strategies are considered. Results suggest that a sterilising vaccine could reduce the HIV incidence between 2015 and 2025 by up to 50%, while a disease modifying vaccine would be unlikely to reduce HIV incidence by more than a third. The effect on AIDS mortality over the same period would be substantially smaller, and it is unlikely that any preventive vaccine would reduce AIDS mortality by more than 10% between 2015 and 2025.

show abstract

Estimation of ?needs? and ?probable uptake? for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study)

Cited by 34 publications

References 13 publications

HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics

HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics

The private demand for an AIDS vaccine in Thailand

The potential effect of an HIV/AIDS vaccine in South Africa

Contact Info

Product

Resources

About